NYSE:PFE - Pfizer Stock Price, Price Target & More

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer declared a quarterly dividend on Thursday, June 28th. Investors of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 dividend on an annualized basis and a yield of 3.64%. The ex-dividend date is Thursday, August 2nd. View Pfizer's Dividend History.

Pfizer declared that its Board of Directors has authorized a share repurchase plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.03. The biopharmaceutical company earned $12.91 billion during the quarter, compared to analysts' expectations of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The firm's revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.69 earnings per share. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pfizer.

Pfizer updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

21 Wall Street analysts have issued 1 year target prices for Pfizer's shares. Their forecasts range from $36.00 to $45.00. On average, they expect Pfizer's stock price to reach $40.4167 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Ratings for Pfizer.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Pfizer saw a decrease in short interest in June. As of June 29th, there was short interest totalling 59,174,572 shares, a decrease of 8.5% from the June 15th total of 64,685,349 shares. Based on an average daily volume of 21,034,138 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.0% of the shares of the company are short sold. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News coverage about PFE stock has trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pfizer earned a coverage optimism score of 0.05 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 44.85 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.66%), Bank of Montreal Can (0.37%), Hexavest Inc. (0.10%), NN Investment Partners Holdings N.V. (0.09%), Swedbank (0.06%) and Gateway Investment Advisers LLC (0.05%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Montreal Can, Swedbank, KAMES CAPITAL plc, Gateway Investment Advisers LLC, Manning & Napier Group LLC, Hamlin Capital Management LLC and BLB&B Advisors LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, DnB Asset Management AS, Pennsylvania Trust Co, Caledonia Investments PLC, Xact Kapitalforvaltning AB and Gulf International Bank UK Ltd. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $37.35.

Pfizer has a market capitalization of $223.41 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.